Evidence map›Paper›PMID 41631282›Full record

ArticleJournal of medical cases2026

Novel Utilization of Circulating Tumor DNA in Primary Dedifferentiated Seminal Vesicle Adenocarcinoma: A Case Report of Molecular Clearance Following Multimodal Therapy.

Kamil Malshy, Brendan J Guercio, Laena Hines, Sarah K Findeis, Philip A Sutera, Shawn W Thomas, Jean V Joseph

Abstract readCase Reports
In one paragraph

Article in Journal of medical cases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kamil MalshyDepartment of Urology, University of Rochester Medical Center, Rochester, NY, USA.ORCID https://orcid.org/0000-0003-4130-8987
Brendan J GuercioJames P. Wilmot Cancer Institute, University of Rochester, Rochester, NY, USA.
Laena HinesDepartment of Urology, University of Rochester Medical Center, Rochester, NY, USA.
Sarah K FindeisDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Philip A SuteraDepartment of Radiation Oncology, University of Rochester Medical Center, Rochester, NY, USA.
Shawn W ThomasFlorida Urology Center, Ormond Beach, FL, USA.
Jean V JosephDepartment of Urology, University of Rochester Medical Center, Rochester, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary seminal vesicle adenocarcinoma (PSVA) is an exceptionally rare malignancy, with fewer than 100 cases reported worldwide and poses significant diagnostic and surveillance challenges due to its deep pelvic location, nonspecific clinical manifestations, frequent coexistence with other genitourinary malignancies, and lack of validated serum tumor markers. A 77-year-old male with long-standing lower urinary tract symptoms and mildly elevated prostate-specific antigen was found to have a large (7.4 cm) predominantly cystic pelvic mass replacing the left seminal vesicle on magnetic resonance imaging. Histologic evaluation revealed synchronous high-grade prostate adenocarcinoma and a distinct dedifferentiated carcinoma not arising from prostatic tissue. Comprehensive immunohistochemical analysis supported a diagnosis of PSVA. The patient underwent robotic-assisted radical prostatectomy with

Indexed as

AdenocarcinomaBiomarkerctDNAProstateSeminal vesicles

Identifiers

PMID41631282
PMCPMC12861512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.